Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex(®)) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion

Macular edema is a common cause of visual loss in patients with retinal vein occlusions. Ozurdex(®), a dexamethasone intravitreal implant, has been shown in randomized controlled trials to reduce macular edema and improve visual acuity in patients with either branch retinal vein occlusions or centra...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Annie, Leung, Loh-Shan, Blumenkranz, Mark S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151568/
https://www.ncbi.nlm.nih.gov/pubmed/21845032
http://dx.doi.org/10.2147/OPTH.S13775
_version_ 1782209631454494720
author Chan, Annie
Leung, Loh-Shan
Blumenkranz, Mark S
author_facet Chan, Annie
Leung, Loh-Shan
Blumenkranz, Mark S
author_sort Chan, Annie
collection PubMed
description Macular edema is a common cause of visual loss in patients with retinal vein occlusions. Ozurdex(®), a dexamethasone intravitreal implant, has been shown in randomized controlled trials to reduce macular edema and improve visual acuity in patients with either branch retinal vein occlusions or central retinal vein occlusions. It was approved in the United States in 2009. Since then, new therapeutic agents and clinical data have emerged. The purpose of this review is to critically evaluate the clinical utility of Ozurdex(®) in the current treatment strategy of macular edema related to retinal vein occlusion.
format Online
Article
Text
id pubmed-3151568
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31515682011-08-15 Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex(®)) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion Chan, Annie Leung, Loh-Shan Blumenkranz, Mark S Clin Ophthalmol Review Macular edema is a common cause of visual loss in patients with retinal vein occlusions. Ozurdex(®), a dexamethasone intravitreal implant, has been shown in randomized controlled trials to reduce macular edema and improve visual acuity in patients with either branch retinal vein occlusions or central retinal vein occlusions. It was approved in the United States in 2009. Since then, new therapeutic agents and clinical data have emerged. The purpose of this review is to critically evaluate the clinical utility of Ozurdex(®) in the current treatment strategy of macular edema related to retinal vein occlusion. Dove Medical Press 2011 2011-07-26 /pmc/articles/PMC3151568/ /pubmed/21845032 http://dx.doi.org/10.2147/OPTH.S13775 Text en © 2011 Chan et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Chan, Annie
Leung, Loh-Shan
Blumenkranz, Mark S
Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex(®)) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion
title Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex(®)) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion
title_full Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex(®)) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion
title_fullStr Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex(®)) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion
title_full_unstemmed Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex(®)) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion
title_short Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex(®)) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion
title_sort critical appraisal of the clinical utility of the dexamethasone intravitreal implant (ozurdex(®)) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151568/
https://www.ncbi.nlm.nih.gov/pubmed/21845032
http://dx.doi.org/10.2147/OPTH.S13775
work_keys_str_mv AT chanannie criticalappraisaloftheclinicalutilityofthedexamethasoneintravitrealimplantozurdexforthetreatmentofmacularedemarelatedtobranchretinalveinocclusionorcentralretinalveinocclusion
AT leunglohshan criticalappraisaloftheclinicalutilityofthedexamethasoneintravitrealimplantozurdexforthetreatmentofmacularedemarelatedtobranchretinalveinocclusionorcentralretinalveinocclusion
AT blumenkranzmarks criticalappraisaloftheclinicalutilityofthedexamethasoneintravitrealimplantozurdexforthetreatmentofmacularedemarelatedtobranchretinalveinocclusionorcentralretinalveinocclusion

Ejemplares similares